Sato K, Tsuchiya S, Minato K, Sunaga N, Ishihara S I, Makimoto T, Naruse I, Hoshino H, Watanabe S, Saitoh R, Mori M
Department of Internal Medicine, National Nishi-Gunma Hospital, Shibukawa, Gunma 377-8511, Japan.
Oncol Rep. 2000 Sep-Oct;7(5):1135-9. doi: 10.3892/or.7.5.1135.
We used cisplatin, vincristine, doxorubicin, and etoposide (CODE) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) weekly for salvage chemotherapy in relapsed or refractory small cell lung cancer (SCLC). We reviewed the medical charts of patients between January 1993 and December 1996 at the National Nishi-Gunma Hospital. Twenty patients were treated with salvage chemotherapy. The overall response rate was 55.0%. The median survival time of extensive disease patients from the start of CODE therapy was 23 weeks and the 1-year survival rate was 21.0%. Toxicities were severe, especially in myelosuppression. CODE could be selected as a salvage therapy for chemotherapy- relapsed SCLC cases.
